The objectives of this study were to evaluate the effects of an ACE inhibitor (fosinopril) and a calcium antagonist (amlodipine) on the urinary albumin and transferringexcretion and their relationship to the blood pressure in essential hypertension. Twenty-four never-treated patients (mean age, 46.4 f 8.9 years) with a diastolic blood pressure between 90 and 114 mm Hg and normal renal function, randomly received amlodipine or fosinopril and, if the diastolic blood pressure was not normalized, doxazosin was added to the therapy. Twenty-four-hour ambulatory blood pressure monitoring and 24-h urine collection for albumin and transferringmeasurements were performed before and after 3 and 6 months of therapy. Diastolic blood pressure was normalized in 23 patients (96Y0). Before treatment, microalbuminuria was present in 509'oof patients. In the amlodipine and fosinopril group, antihypertensive therapy significantly decreased blood pressure and, only in the fosinopril group, albuminuria. Transferrinuria did not change significantly in both groups. Fosinopril lowered albuminuria in all patients, whereas amlodipine only in half of patients. Albuminuria, but not transferrinuria, was significantly correlated to the ambulatory blood pressure. This correlation was more pronounced for systolic than for diastolic pressure. In essential hypertensive patients with normal renal function, a high prevalence of microalbuminuria can be observed. Albuminuria appears to correlate with ambulatory blood pressure, particularly with systolic pressure. Intrarenal hemodynamic changes seem to play a more important role than systemic blood pressure decrease in the reduction of albuminuria. Transferrinuria does not seem a useful marker to follow-up nondiabetic hypertensive patients with early signs of glomerular dysfunction. Am
lar morbidity and death in diabetic patients.1-3 Some studies have also shown that microalbuminuria may be a predictor of cardiovascular morbidity and mortality in elderly patients4 and in the general populations The clinical and prognostic significance of microalbuminuria in essential hypertension remains to be ascertained. It is probable that this marker can have the same predictive value in hypertensive patients, even if, to date, no prospective study is available on this issue. In fact in patients with essential hypertension, microalbuminuria is associated with potentially pathogenic factors for cardiovascular compli-cations, ie, an impaired insulin sensitivity and altered lipid levels, h77and might be a marker of systemic endothelial dysfunction.8 The effect of the hypotensive treatment on microalbuminuria in normotensive and hypertensive diabetic patients is largely known; several investigators have reported that angiotensin converting enzyme (ACE) inhibitors can decrease UAE, Y-'7whereas dihydropyridine calcium antagonists may or may not have an affect.y-" Conversely, there are less data regarding the effect of hypotensive therapy on microalbuminuria in nondiabetic hypertensive patients. 's-z' Some studies have shown that determination of urinary transferring excretion (UTE ) is more sensitive than determination of UAE for early detection of glomerular impairment in diabetics. zz-zhThe molecular size and radius of albumin (66 kDa; 3.6 nm) is less than transferring(77 kDa; 3.8 nm),222s whereas transferringis much less anionic than albumin (the isoelectric point is 5.7 u 4.9) .22The relative increase in UTE in diabetes might reflect changes in anionic charge2s or pore size in the glomerular basement membrane,23 increase in negative charge of albumin when glycated,2~>24 or differential tubular excretion/ reabsorption of albumin and transferrin.227242G Our study was designed to evaluate prospectively the effects of an ACE inhibitor (fosinopril) and a dihydropyridine calcium antagonist (amlodipine) on UAE and UTE in a group of never-treated patients with essential hypertension and no sign of renal damage and the relationship of UAE and UTE to the blood pressure (BP).
METHODS
The study population consisted of 24 patients (23 men and 1 woman; mean age, 46.4 t 8.9 years; range, 26 to 62 years) with essentialhypertension. Patients with clinical or laboratory evidence of renal disease, obesity, or diabetes mellitus were excluded. No patient had ever taken any kind of antihypertensive drugs. Patients were included in the study if their diastolic BP was persistently between 90 and 114 mm Hg during three subsequent visits to the outpatient hypertensive clinic, 1 week apart, and if conventional semiquantitative test strips gave a negative result for proteinuria. During the baseline evaluation period, clinical history, physical examination, and laboratory profile were obtained. Blood pressure was measured with a standard mercury sphygmomanometer after the patients had been in a supine position for at least 5 min and in the standing position for 1 min. Three readings were made in a supine position and the average was used for analyses. Baseline BP value was defined as the average of the three measurements taken at the third visit. Before initial treatment the following instrumental examinations were carried out: 12-lead electrocardiogram, chest roentgenogram, and 24-h ambulatory BP monitoring. Furthermore, after fasting overnight for at least 12 h, all patients came to the outpatient clinic and blood samples were drawn for peripheral renin activity, aldosterone and atrial natriuretic peptide levels after subjects had rested 30 min in the supine position and routine biochemistry (complete blood count, serum urea nitrogen, creatinine, glycosylated hemoglobin, triglycerides, total and high density lipoprotein cholesterol, uric acid, sodium, potassium and urinalysis). Twenty-four-hour urine collections were obtained to measure the urinary excretion of creatinine, UAE, and UTE with the patients admitted to our department to assure a correct urine collection and to avoid physical activity altering the UAE. These instrumental and biochemical examinations, except chest roentgenogram, were repeated after 3 and 6 months of therapy. The eligible patients were kept on their habitual diet and randomly received an oral dose of either amlodipine (5 or 10 mg) or fosinopril (10 or 20 mg ) once daily. The administration of the drugs was open-labeled. The goal of therapy was to lower the supine diastolic BP to less than 90 mm Hg. Follow-up visits took place every 2 weeks during the first month and every 4 weeks for the following 5 months. At each visit supine and standing BP as well as heart rate and weight were recorded. After 3 months if the BP was not normalized, doxazosin (2 or 4 mg once daily) was added to the therapy.
Ambulatory Blood Pressure Monitoring Twentyfour-hour BP monitoring was performed by a portable, noninvasive recorder (Medilog, Oxford Medical, England), validated according to the criteria of the American Association for Medical Instrumentation and of the British Hypertension Society.27This monitor uses an algorithm that gates the Korotkoff sounds to the Rwave from the electrocardiogram, allowing validation of a good R-wave signal in all patients. Before patients left the clinic, microphone placement was evaluated for agreement between monitor-derived Korotkoff sounds and those auscultated by mercury sphygmomanometer through a T tubeconnector. Blood pressurereadingswere obtainedautomaticallyat 15-minintervalsduringwaking hours and at 30-min intervals during sleep. All patients underwentambulatoryBP monitoringas outpatientsduring a working day. We used the criteria of Appel and colleagueszgto delete single BP readings.
The effects of the therapy on ambulatory BP values were analyzedas means for the entire 24-h period and its subsets of time (ie, awake and asleep) and according to the methodof White andco-workers.29These investigators proposedcut-off valuesfor abnormallyelevatedreadings of 140/90 mm Hg for the waking period and 120/ 80 mm Hg for the sleeping period, on the basis of data in normotensiveandhypertensivecohorts.29We assessed the numberof abnormallyelevatedBP values duringthe 
RESULTS
Effects of Amlodipine and Fosinopril Baseline patient characteristics in the groups of patients receiving amlodipine (group A) and fosinopril (group F) are shown in Table 1 . No significant difference was observed. All patients took the maximal dose of either amlodipine or fosinopril; in each group, 3 patients (25%) required the addition of doxazosin (4 mg daily) to the initial regimen. Diastolic BP values were normalized in all patients of both groups, except one in the group F. A significant reduction in office supine and standing BP was already evident in both groups at 2 weeks, whereas heart rate was not significantly affected during the study. Data from ambulatory BP monitoring in groups A and F are shown in Figure 1 . No significant difference between baseline BP measurements in the two groups was observed. Ambulatory BP was significantly decreased by amlodipine and fosinopril by the third month, as well as 24-h BP load, although the decrease in group A was a little greater than that in group F (Figure 2 ). The same results were obtained in both groups when using the analysis of variance (P< .001).
No significant change in weight was observed in the two groups at 3 and 6 months.
Before treatment, UAE and creatinine clearance values were higher in group A, even if not significantly. After drug therapy, UAE significantly decreased in group F, whereas in group A a nonsignificant reduction at the third month and an increase at the sixth month was observed (Table 2) . At baseline microalbuminuria was present in 7 (5870) of group A patients and in 5 (4270) of group F patients, whereas at the end of the study in 8 (67??.) and in 1 (8Y0) of groups A and F, respectively (Figure 3 ). Fosinopril lowered UAE in all patients, whereas amlodipine decreased UAE in 6 patients and increased it in the other half of patients at the end of the study (Figure 3) . Creatinine clearance decreased in group A and increased in group F at 3 months and returned to the initial values in both groups at 6 months ( Table 2) . UTE showed a nonsignificant trend toward a reduction in both groups; it was more evident in group F (Table 2) . Similar results were obtained when using the analysis of variance; a significant change in UAE was observed only in group F (P < .001).
No significant change in routine biochemical values was found. Aldosterone significantly decreased in group F and increased in group A, whereas renin activity significantly increased in group F and remained constant to the end of the study in group A ( Correlations A significant positive correlation was found between UAE and UTE before treatment (r = 0.55, P < .01), but not at 3 and 6 months of therapy.
No significant relationship between creatinine clearance and UAE or UTE was observed at baseline and during the study period.
At baseline UAE, but not UTE, correlated with 24-h, waking, and sleeping systolic BP (r = 0.56, r = 0.55, P <.01, and r = 0.45, P <.05, respectively) and with 24-h systolic and diastolic BP load (r = 0.61, P <.001, and r = 0.45, P < .05, respectively). These correlations were not confirmed at 3 and 6 months. No relationship between UAE or UTE and office BP as well as the indices of BP variability (24-h, awake and asleep BP standard deviations and the ratio of awake to asleep BP) was observed. If the differences between baseline and 3 or 6months values of BP, UAE, and UTE were considered,
In the multiple regression analysis, UAE was signifithere was a better correlation between BP and UAE, cantly associated only with aldosterone (regression cobut not with UTE (Table 3) . efficient and 959i0confidence limits: 0.023, 0.011-0.034, No significant relationship between UAE or UTE and P = .0004) and with 24-has well as waking and sleeping plasma hormones was observed, except for between BP (0.019, 0.008-0.030, P = . 002, 0.018, 0.007-0.029 , P UAE and aldosterone and only at baseline (r = 0.61, P < .003, and 0.014, 0.003-0.025, P < .02, respectively) < .001).
and only at baseline. Side Effects Peripheraledema was present in 3 of 12 patients (25!7.) in group A, but this did not lead to withdrawal from therapy. No other adverse reactions in both groups were observed or referred.
DISCUSSION
The true prevalence of microalbuminuria in essential hypertension is not well known; it has been shown to occur in 1470to 4070 of hypertensive patients sl-34and the different prevalence in these studies might be related to different selection criteria (ie, age, race, the severity of hypertension, the enrollment of treated or untreated patients, the degree of BP well controlled, the coexistence of renal insufficiency). In our study, microalbuminuria was present in 50'%. of patients with never-treated essential hypertension and no sign of renal damage. This prevalence is based on the analysis of a single 24-h urine collection and could be criticized. In fact, it is generally agreed that UAE is very variable and, according to some investigators, the definition of microalbuminuria should be based on the median UAE in at least three urine samples collected over several months.35However, the following considerations should be taken into account. First, whether a patient's risk status is influenced by the degree of variation of UAE around a risk level or whether the classification of risk is improved by multiple collections awaits testing in prospective studies. Second, nearly all epidemiologic studies showing that microalbuminuria is an independent predictor of cardiovascular morbidity and mortality in diabetic and nondiabetic subjects, performed a single urine collection to determine UAE1-5'3G-38; most of these studies even used overnight urine samples, which are less sensitive than 24-h urine collections in identifying patients with incipient nephropathy.3940Third, several studies have shown that a single urine collection can be used to identify correctly patients with microalbuminuria.34'40-42 Fourth, in this study 24-h urine collections were obtained while the patients were admitted to the department to avoid possible factors influencing UAE. Finally, it should also be kept in mind that multiple 24-h urine collections are often impractical in outpatient settings.
Effects of Amlodipine and Fosinopril on Urinary Albumin Excretion Before treatment, patients in group F were characterized by a significantly lower creatinine clearance value and by a lower, but not significant value of BP than patients in group A. It is improbable that lower creatinine clearance values in group F could reflect a higher degree of renal vascular damage due to hypertension, both because these values were in the normal range and because baseline UAE value and prevalence of microalbuminuria were lower in group F than in group A. After drug therapy, BP significantly decreased in both groups, even if a little more in group A, whereas only group F showed a significant reduction in UAE. Moreover, fosinopril lowered UAE in all patients, whereas amlodipine did so only in half of the patients. Our findings are in agreement with previous anima143and human studies 1819 on essential hypertension showing a preferential effect of ACE inhibitors, versus other hypertensive drugs, in reducing elevated levels of UAE. Conversely, other investigators reported a similar effect on microalbuminuria of calcium antagonists and ACE inhibitors.20f21 A metaregression analysis assessing the relative effect of different antihypertensive agents on proteinuria and renal function in diabetic patients concluded that any drug that reduces BP also decreases proteinuria.44Nevertheless, it was evident from this study that unlike other antihypertensive agents, ACE inhibitors can reduce proteinuria and preserve renal function independently of changes in systemic BP. In fact, several studies on diabetic patients have shown that microalbuminuria can also be reduced in normotensive subjects.9J1]-15 Although the pathophysiologic mechanisms involved in proteinuria in diabetes and in essential hypertension may be different, recently in another meta-analysis, Maki and coworkers45showed that long-term beneficial effects of hypotensive agents on proteinuria and glomerular filtration rate are proportional to BP reductions and similar in diabetic and nondiabetic patients with renal disease and, moreover, that ACE inhibitors have additional beneficial effects on proteinuria independently of BP reductions. Therefore, it is probable that other factors, besides systemic BP, can play a role in the development of microalbuminuria. The different effects of calcium antagonists and ACE inhibitors on microalbuminuria in essential hypertension observed in our, as well as in other studies 18'19;4s may be attributable to different hemodynamic intrarenal effects of these two classes of antihypertensive agents and are similar to those re-ported in diabetes mellitus.')'"12-1°Experimental data suggest that high intraglomerular capillary pressure may play an important role in glomerular injury.4bThe ACE inhibitors reduce glomerular capillary pressure by dilating efferent more than afferent glomerular arterioles43,47-4Y and probably by relaxing mesangial cells and increasing the ultrafiltration coefficient.4s47Reduction in intraglomerular pressures would reduce macromolecular traffic through the mesangium and prevent endothelial injury.47Moreover, it has also been reported that these agents can reduce glomerular permeability.48 Conversely, because calcium antagonists preferentially dilate the afferent arteriole,soit has been proposed that these drugs should theoretically favor an increase in glomerular capillary pressure.sl In fact, Buzio and coworkerssz have reported that in essential hypertensive patients single doses of nifedipine, preceding a protein load, raised both glomerular filtration rate and renal plasma flow and increased urinary protein excretion rate, whereas captopril did not. Finally, the favorable effects of ACE inhibitors on microalbuminuria are likely also attributable to nonhemodynamic mechanisms due to inhibition of the renin-angiotensin-aldosterone system, such as a reduction in mesangial proliferation4748by suppressing angiotensin II and a vascular protective effect at the endothelial level by sparing potassium.475sIn confirmation of this last issue, in our study fosinopril significantly decreased aldosterone, whereas amlodipine increased it and, before treatment, a positive correlation between UAE and aldosterone was observed.
Effects of Amlodipine and Fosinopril on Urinary
Transferring Excretion UTE did not significantly change during the study in both groups, whereas a significant decrease in UAE, at least in group F, was observed by the third month. Blood pressure was already significantlyreduced after 2 weeks of therapy in both groups. Bianchi and coworkersls reported a significantreduction in BP and UAE after4 weeks of ACE inhibitor therapy. Therefore, we might conclude that UAE is sensitiveto short-term changes in systemic BP, whereas UTE does not seem to be influenced by afterload reduction and it appears less sensitive than UAE for early detection of glomerular dysfunction in essentialhypertension.In fact, in our study the UTE of patients with microalbuminuria was remarkably less than in diabetic patients, but similar to healthy subjects reported by Martin and coworkers.22The different results observed in diabetes patients22-2bmight be explained by changes in anionic charge of the glomerular basement membrane with nonenzymatic glycosylation25 or by the fact that, when glycated, albumin becomes much more anionic and thus more repelled by the glomerular polyanion basement membrane than transferrin.2324In confirmation of our findings, Konen and coworkerss4 observed that UTE was less elevated than UAE in hypertensive patients without diabetes.
Relationship Between Urinary Transferringand AIbumin Excretion and Blood Pressure No correlation between UTE and BP was observed, whereas UAE was significantly and positively correlated to ambulatory BP, both as mean and BP load, but not to office BP.
Some investigatorsgs] reported a significant correlation between office BP and UAE, but others did not.33A weak, even if significant, correlation with office BP (from r = 0.23 to r = 0.34) was observed by Hoegholm and coworkers, q4whereas the same and other investigators found a significantly stronger correlation between UAE and ambulatory BP. In this study as well as in another studys4 a more pronounced correlation for systolic than for diastolic BP was found.
In conclusion, in these patients with never-treated essential hypertension and without signs of renal function impairment, a high prevalence of microalbuminuria has been observed. Antihypertensive therapy, particularly with an ACE inhibitor agent, shows to have a favorable effect on UAE. This finding might suggest that intrarenal hemodynamic changes can play a more important role than systemic BP decrease. A significant correlation has been found between UAE and BP with ambulatory, but not with office measurements, and it was more pronounced for systolic than for diastolic BP. UTE does not seem as useful a marker to follow-up essential hypertensive patients with early signs of glomerular dysfunction.
The clinical implications of these observations on the initial changes of renal function in essential hypertension remain to be ascertained.
